Skip to main content
Signal8

Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen

$BIIBPress releaseJun 29, 2026, 6:59 AM ET

Biogen announced it will present Phase 2 CELIA data for its investigational tau-targeting therapy diranersen (BIIB080) and new analyses for LEQEMBI at the Alzheimer’s Association International Conference (AAIC) 2026. The diranersen presentation will cover clinical, biomarker, and safety results from an 18-month study involving 416 patients with early Alzheimer’s disease, building on topline results released in May 2026.

Key figures

Drug Name
Diranersen (BIIB080)
Phase Of Trial
Phase 2
Pdufa date
2026-08-24
Celia participants
416
Primary endpoint week
76
Study duration months
18
Leqembi approval countries
53

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.